! I’m your host today, Jessica Hergert.

, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, 

 covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Takeda, we had the pleasure of speaking with John V. Heymach, MD, PhD, chair, professor, and David Bruton, Jr Chair in Cancer Research in the Department of Thoracic/Head and Neck Medical Oncology, and professor in the Department of Cancer Biology, Division of Cancer Medicine at The University of MD Anderson Cancer Center, to discuss 

 20 insertion–mutated non–small cell lung cancer (NSCLC).

In our exclusive interview, Heymach discussed the incidence of 

 exon 20 insertions in lung cancer, diagnostic challenges of identifying 

 exon 20 insertions, and data from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer with mobocertinib and amivantamab in this patient subset.

Podcasts

that provides oncology professionals with the resources and information they need to provide the best patient care. Segments cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. New episodes with exclusive interviews with leading oncology experts are released on Mondays and Thursdays. 

Lung Cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Precision Medicine in Oncology®

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Publications

® Publications page showcases all of the exclusive content that appears in the twice-monthly print publication 

 Multiple print supplements that run in tandem with 

, including meeting reporters, priority reports, My Treatment Approach, and Year in Review publications, can all be found on this Publications page. 

Oncology Expert Insights

Uncommon EGFR Mutations in Non–Small Cell Lung Cancer 

Scientific Interchange & Workshop

The University of Texas MD Anderson Cancer Center

Cancer Centers

Partner

John V. Heymach, MD, PhD, discusses the incidence of EGFR exon 20 insertions in lung cancer, diagnostic challenges of identifying EGFR exon 20 insertions, and data from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer with mobocertinib and amivantamab in this patient subset.

Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC